America and Britain Sign No-Tariff Arrangement on Prescription Drugs.

Britain and America have secured a major trade agreement that will keep no import taxes on UK pharmaceutical products entering the US market.

Key Provisions of the Pact

Under the terms of the agreement, the UK has pledged to increase funding on drugs through the public health system. This move secures that duties on these key products will stay at nothing for a period of 36 months.

This development comes after earlier warnings to dramatically increase duties on patented pharmaceutical imports, with potential rates floated as high as 100%.

"This arrangement with the Britain reinforces the global environment for cutting-edge drugs and establishes long-overdue balance to American-British pharmaceutical trade," a release noted.

Trade Importance

Pharmaceuticals represent one of the UK's biggest export categories to the United States, which is by far the primary destination for major UK drugmakers.

Statistics show that in the 12 months prior to last September, the UK exported drugs totaling over eleven billion pounds to the US. This figure represented a significant portion of all goods exports in that timeframe.

"This agreement secures employment, stimulates funding and facilitates the UK to become a international leader for life sciences," the Business and Trade Secretary commented.

Specific NHS Changes

The pact involves several key changes from the United Kingdom:

• Price Threshold Increase: The UK will increase the affordability limit at which it judges new treatments to be unaffordable by twenty-five percent.
• Boosted Medicine Funding: There is a aim to double overall public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
• Rebate Cap: The amount pharmaceutical firms must refund to the NHS to control costs will be capped at 15%. In the past, rebates topped twenty percent.

Recent Tensions

This agreement comes amid a protracted tension between the pharmaceutical industry and the UK government over spending levels and approval rates.

This friction were intensified by assertions that American consumers were charged significantly more for the equivalent treatments than consumers in the other developed nations.

In recent months, several major pharmaceutical investments in the UK have been halted or abandoned, while substantial expansions have been announced toward projects in the United States.

One official stated that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a percentage of its resources over the previous ten-year period.